SCHEMBL30910045

SCHEMBL30910045

CC(C)CN1CCN(C(=O)CN2CCCCC2)c2ccccc21

nearest known ligand 0.51

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.51
POLB P06746 2/20 0.51
KDM4E B2RXH2 2/20 0.51
PKM P14618 1/20 0.51
USP2 O75604 1/20 0.46
ALOX15 P16050 1/20 0.46
RAD52 P43351 1/20 0.45
MAPT P10636 3/20 0.43
BRD4 O60885 1/20 0.43
NPC1 O15118 1/20 0.42
NR1I3 Q14994 1/20 0.41
DRD2 P14416 1/20 0.40
DRD4 P21917 1/20 0.40
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
GAA P10253 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26091906 1.00 ALDH1A1 (0.51) ALDH1A1POLBKDM4EPKMUSP2
SCHEMBL30910082 0.99 ALDH1A1 (0.52) ALDH1A1POLBKDM4EPKMUSP2
SCHEMBL26088477 0.99 ALDH1A1 (0.52) ALDH1A1POLBKDM4EPKMUSP2
SCHEMBL26088955 0.88 ALDH1A1 (0.45) ALDH1A1POLBKDM4EPKMMAPT
SCHEMBL30379642 0.88 ALDH1A1 (0.45) ALDH1A1POLBKDM4EPKMMAPT
SCHEMBL26090549 0.87 ALDH1A1 (0.45) ALDH1A1POLBMAPTBRD4DRD2
SCHEMBL30910043 0.87 ALDH1A1 (0.45) ALDH1A1POLBMAPTBRD4DRD2
SCHEMBL26091237 0.83 ALDH1A1 (0.52) ALDH1A1POLBKDM4EPKMUSP2
SCHEMBL30910069 0.83 ALDH1A1 (0.52) ALDH1A1POLBKDM4EPKMUSP2
SCHEMBL30378895 0.82 BRD4 (0.48) ALDH1A1POLBMAPTBRD4MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250002464-A1 NOVEL COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME SAPIENSBIO INC. (KR) 2025-01-02 US claimed
EP-4421070-A1 NOVEL COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME Sapiensbio Inc. (KR) 2024-08-28 EP claimed
CN-118119612-A Novel compounds and pharmaceutical compositions comprising the same 萨皮恩斯生物有限公司 2024-05-31 CN claimed
US-20250002464-A1 NOVEL COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME SAPIENSBIO INC. (KR) 2025-01-02 US disclosed
EP-4421070-A1 NOVEL COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME Sapiensbio Inc. (KR) 2024-08-28 EP disclosed
CN-118119612-A Novel compounds and pharmaceutical compositions comprising the same 萨皮恩斯生物有限公司 2024-05-31 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250002464-A1 NOVEL COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME RHOA, ACTR2, MFAP1 ALDH1A1 2159/4885POLB 3983/4885KDM4E 1932/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.